We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Strontium89

News List

Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada americanpharmaceuticalreview
August 11, 2021
Q BioMed Inc., a commercial-stage biotech company, announced that it recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing services and solutions to ...
Q BioMed Inks Strontium89 Supply Pact contractpharma
March 03, 2021
Q BioMed Inc. has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injection, USP) to be included on the Federal Supply Schedule (FSS).
Global distribution partnership established for Strontium89 europeanpharmaceuticalreview
July 14, 2020
Q Biomed entered into a Named Patient Programme distribution agreement for Strontium89, a non-opioid metastatic bone cancer pain drug.
Q BioMed Enters $7.8M Financial Restructuring contractpharma
April 09, 2020
Provides capital to bring FDA approved non-opioid, Strontium89 Chloride USP Injection drug to market.
Q BioMed Appoints Head of Global Regulatory Affairs contractpharma
April 01, 2020
Geoff Fatzinger will lead the global regulatory approval strategy for the commercialization of FDA approved, non-opioid Strontium89.